Form 4: Shattuck Labs Director Acquires Significant Stock Options

Shattuck Labs, Inc. Director George Golumbeski has acquired 33,150 stock options with an exercise price of $0.82, vesting on the earlier of one year or the next annual meeting.

Summary

• George Golumbeski, a Director of Shattuck Labs, Inc. (STTK), was granted 33,150 stock options.
• Each option has an exercise price of $0.82.
• The options are set to expire on July 14, 2035.
• The options will vest in full on the earlier of the one-year anniversary of the grant date (July 14, 2025) or immediately prior to the Issuer's next annual meeting of stockholders, contingent on Mr. Golumbeski's continued service to the Issuer.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates director alignment with shareholder interests through equity compensation, a standard and generally well-received practice.

Positives

• The acquisition of stock options by a director aligns management's interests with those of shareholders, as the value of the options is tied to the company's stock performance.
• The grant of options is a common form of equity compensation, indicating ongoing commitment to attracting and retaining qualified board members.

Future Outlook

The stock options are subject to vesting conditions, requiring continued service to the Issuer until the earlier of the one-year anniversary of the grant date or immediately prior to the next annual meeting of stockholders, indicating an expectation of continued engagement from the director.

Industry Context

The grant of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, aligning the interests of board members with long-term shareholder value creation. This transaction reflects a routine compensation event within the sector.

Comparison to Industry Standards

• Option grants to directors are a common component of compensation packages across publicly traded companies, including those in the biotech sector like Shattuck Labs.
• The vesting schedule, tied to continued service and a one-year anniversary or next annual meeting, is typical for director equity awards, similar to practices observed at comparable companies such as Moderna (MRNA) or BioNTech (BNTX) for their non-employee directors.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of stock options from Shattuck Labs, Inc. to George Golumbeski, a Director of the company, constituting a related party transaction.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders if the stock price increases.
• Employees: While not directly impacted, such grants are part of a broader compensation philosophy that can influence overall employee morale and retention.

Next Steps

• The stock options will vest on the earlier of July 14, 2026 (one-year anniversary of grant) or immediately prior to the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Shattuck Labs, STTK, stock options, insider transaction, director compensation, equity grant, corporate governance